Scandinavian Prostate Cancer Group
A research organisation working with clinical trials for progression of the prostate cancer care.
Our clinical studies
Read about our projects
In the first two decades of the new millennium there has been a increasing understanding of diagnosis, treatment and prognosis. The results of the SPCG-trials will be presented at this homepage with the goal to give you a good overview of the ongoing studies and updated information of the results.
Two randomized clinical trials are stil including patients. The SPCG-15 study is randomizing locally advanced prostate cancer to either radiotherapy or surgery. The second trial including patients is the SPCG-17 randomized trial of active surveillance including one arm with standardized triggers for curative treatment versus a control arm with clinical practice. The SPCG-14 stoped inclusion 2018 and the first results are analyzed.See trials
Finished SPCG-trials include for example randomization between surgery and watchful waiting (SPCG-4), the addition of radiotherapy to androgen deprivation therapy in locally advance prostate cancer (SPCG-7), adjuvant docetaxel in addition to surgery (SPCG-12) and radiotherapy (SPCG-13) respectively. Pleas find more about all the trials at our homepage.See trials
82 publications in total
Here you find the updated publications from the SPCG-trials
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study
Lehtonen M, Sormunen J, Hjälm-Eriksson M, Thellenberg-Karlsson C, Huttunen T, Ginman C, Kellokumpu-Lehtinen PL; Investigators of the Scandinavian Prostate Cancer Group Study No 13.
Anticancer Res. 2022 JanSPCG-13
Second Cancers in Patients With Locally Advanced Prostate Cancer Randomized to Lifelong Endocrine Treatment With or Without Radical Radiation Therapy: Long-Term Follow-up of the Scandinavian Prostate Cancer Group-7 Trial
Bjørg Y Aksnessæther, Tor Åge Myklebust, Arne Solberg, Olbjørn H Klepp, Eva Skovlund, Solveig Roth Hoff, Sophie D Fosså, Anders Widmark, Jo-Åsmund Lund
J Radiat Oncol Biol Phys
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial
Pirkko-Liisa Kellokumpu-Lehtinen, Marie Hjälm-Eriksson, Camilla Thellenberg-Karlsson, Lennart Åström, Lars Franzen, Ann-Sofie Fransson, Markku J Leskinen, Mihalj Zeke, Teppo Huttunen, Claes Ginman, Investigators of the Scandinavian Prostate Cancer Study No. 13
Mats Steinholtz Ahlberg, Hans-Olov Adami, Kerri Beckmann, Helena Bertilsson, Ola Bratt, Declan Cahill, Lars Egevad, Hans Garmo, Lars Holmberg, Eva Johansson, Antti Rannikko, Mieke Van Hemelrijck, Fredrik Jäderling, Cecilia Wassberg, Ulrika W N Åberg, Anna Bill-Axelson
Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort.
Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W.
Radiother Oncol. 2019
To help you in your daily work, the SPCG welcomes you to our website for further information. You may find important news from the SPCG, updated results of our protocols, abstracts from meetings, information about forthcoming meetings and published clinical research. Important links to other pages related to prostate cancer are included. We hope you will find these pages useful and informative.